Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey

Creative Commons License

Cicek D., PEKDEMİR H., Haberal C., KALAY N., Binici S., Altay H., ...More

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol.8, no.1, pp.68-73, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 1
  • Publication Date: 2011
  • Doi Number: 10.7150/ijms.8.68
  • Journal Name: INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.68-73
  • Keywords: coronary artery disease, drug-eluting stent, major adverse cardiac event, stent thrombosis, BARE-METAL STENTS, SLOW-RELEASE, DOUBLE-BLIND, II TRIAL, IMPLANTATION, SIROLIMUS, THROMBOSIS, TAXUS, MULTICENTER, OCCLUSION
  • Akdeniz University Affiliated: Yes

Abstract

Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world.